Chuck Morrison serves as a Senior Advisor at Outcome Capital’s diagnostics and biotechnology practices. He brings significant expertise and a track record in successfully structuring, negotiating and executing acquisitions, licensing, partnerships, and distribution transactions. Chuck is a business development executive with over thirty years of life science, biotechnology and diagnostic expertise, including 13 years of corporate business development. He is a leader in the life science sector with proven business acumen, international experience, integrity, strategic vision and focus on execution. Known for driving results and overcoming difficult challenges.
Chuck is currently a non-executive Board Member for GenePOC, Inc., a molecular diagnostic company developing point-of-care platforms for the rapid detection of infectious diseases (recently acquired by Meridian Bioscience). He is also Head of Business Development at Proteomics International, Perth, Australia. PI has developed a proprietary mass spectrometry biomarker discovery platform and has recently discovered biomarkers for the diagnosis of diabetic kidney disease. Previously, Chuck held various managerial positions at PerkinElmer, NEN Life Sciences and DuPont Medical Products.
Chuck is currently providing strategic consulting services to early-stage and smaller biotech companies, positioning toward merger & acquisitions, partnerships, licensing and joint ventures, as well as team building, product commercialization and carving out a path to commercialization.